Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Bjerrum (Aarhus, Denmark), T. Skjold (Aarhus, Denmark), H. Andersen (Aarhus, Denmark), L. Pedersen (Aarhus, Denmark), J. Schmid (Aarhus, Denmark). Changing between anti-IL5 and anti-IL5 receptor treatments. A real-life study. 1652

Member's Comments

No comment yet.

Related content which might interest you: Oral glucocorticoid-sparing effects of mepolizumab. A real-life study. Source: International Congress 2018 – Innovative therapies in asthma and COPD Year: 2018 Evaluating response to omalizumab (anti-IgE) in clinical practice Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005 Late Breaking Abstract - Preclinical study of anti-interleukin-4 alpha single domain antibody with therapeutic potential in asthma by oral inhalation Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 Characteristics of patients receiving mepolizumab in real-world practice –REALITI-A study Source: International Congress 2018 – New developments in the treatment of asthma Year: 2018 Adherence to omalizumab: a “real-life” study Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Real-world treatment patterns of mepolizumab therapy in Canada Source: Virtual Congress 2020 – Management of chronic lung conditions Year: 2020 Use of Omalizumab in children in real clinical practice. Source: Virtual Congress 2021 – Paediatric allergic asthma: novel therapeutics and monitoring approaches Year: 2021 Anti-IgE therapy: rationale and clinical evidence Source: Annual Congress 2007 - Changing practice with anti-IgE: patient, physician and payor perspectives Year: 2007 CXCL-8-dependent and -independent neutrophil activation in COPD: experiences from a pilot study of the CXCR2 antagonist danirixin Source: ERJ Open Res, 6 (4) 00583-2020; 10.1183/23120541.00583-2020 Year: 2020 Mepolizumab improves lung function under real-world settings in REALITI-A study Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020 Real-world treatment patterns of benralizumab therapy for patients with severe asthma Source: Virtual Congress 2020 – Diagnosis and management of asthma Year: 2020 Predictors of effectiveness of omalizumab treatment in patients with severe asthma recruited in a real-life setting Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 IL-2 intravenous application as one of the new ways of immunomodulative therapy of the asthmatic patients Source: Eur Respir J 2002; 20: Suppl. 38, 589s Year: 2002 Effectiveness of anti-IgE and anti-IL-5 treatment in step 5 asthma patients. Source: International Congress 2018 – Role of IgE and interleukin (IL)-5 in Th2-cell signatures Year: 2018 Comparative efficacy of the therapy strategies for the asthma control maintenance in real clinical practice Source: Annual Congress 2011 - Asthma: control and treatment Year: 2011 Long-term oral corticosteroid-sparing effects of anti-IL5/anti-IL5 receptor treatment. Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021 A novel anti-IgE immunotherapeutic, RP01, induces anti-IgE antibodies in human subjects; data from a phase I study Source: Eur Respir J 2007; 30: Suppl. 51, 622s Year: 2007 Efficacy and safety of pirfenidone in patients with IPF. A single center real-life experience. Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside Year: 2017 Assessment of a responder identification treatment algorithm for omalizumab in a naturalistic setting Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities Year: 2007